Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Through its innovative asymmetric siRNA platforms, OliX Pharmaceuticals is opening up huge opportunities in RNA interference-therapeutic development to address unmet needs for various indications spanning the liver, eye, skin, and beyond.
Azor Biotek is applying artificial intelligence solutions to the design and development of tailored, highly specific, novel small molecules, tapping into the vast potential of RNA drug targets.
Cancer Research Horizons (CRH) is harnessing the skills, expertise, and research network of its parent organization to speed-up the discovery and development of transformative oncology drugs, improve patient outcomes, and advance assets for biopharma partners.
Visionary investment in mRNA technology platforms is allowing ST PHARM and its two startups, Levatio Therapeutics and Vernagen, to foster partnerships and advance the development of cutting-edge RNA-based drugs and vaccines.
NurExone has created ExoTherapy, a cutting-edge exosome-based drug-delivery platform, and is currently developing its lead product, ExoPTEN, as a novel therapy for acute spinal cord injuries.
UK-based Broken String Biosciences is developing a commercial analytics platform for CRISPR therapeutics safety, a space in growing need of a gold standard solution for measuring off-target gene editing.
As Pandorum Technologies’ bioengineered ‘liquid cornea’, Kuragenx, is about to enter a first-in-human study for vision restoration in patients suffering from corneal blindness, the company is extending its proprietary technology platform to develop advanced exosome-based therapeutics for lung and liver regeneration.
With its unique and proprietary genetically modified adipocyte (GMAC) platform, CellGenTech is developing novel ex vivo gene therapies and has achieved the first-in-human study of an adipocyte-based gene therapy.
Pennsylvania-based Ocugen is a fully integrated, patient-centric biotech company focused on the development of vaccines in support of public health, and gene and cell therapies targeting unmet medical needs, all based on its three scientific platforms.
By engineering naturally existing arrestin domain-containing protein 1 (ARRDC1)-mediated microvesicles (known as ARMMs), Vesigen Therapeutics’ platform enables the effective delivery of novel biotherapeutics to specific tissues and cell types.
bit.bio is a synthetic biology company that uses its cell identity coding platform to reprogram induced pluripotent stem cells to create any human cell type.
Rapidly responding to the needs of the evolving oncology landscape, AstraZeneca is focused on sourcing transformational programs and technologies, whilst nurturing mutually beneficial partnerships to deliver innovative treatment strategies to patients.
One-carbon Therapeutics has developed a novel method to target the vulnerability of cancer cells that interrupts a pathway used by tumor cells to maintain a high rate of proliferation.
Vaccination saves two to three million lives annually. GSK will continue delivering proven vaccines, expand their availability to populations in need, and create new vaccines to protect against endemic and emerging diseases. To those who possess novel technologies that can innovate vaccine creation, GSK ventures to be your partner of choice.
TiCARos, a South Korean biotech, aims to revolutionize cancer treatment with its advanced chimeric antigen receptor T cell (CAR-T) therapeutics and technologies that target both blood cancers and solid tumors.